These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 21425312)

  • 21. Proteome responses to stable hepatitis B virus transfection and following interferon alpha treatment in human liver cell line HepG2.
    Wang J; Jiang D; Zhang H; Lv S; Rao H; Fei R; Wei L
    Proteomics; 2009 Mar; 9(6):1672-82. PubMed ID: 19242931
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antitumor effect of an adeno-associated virus expressing apolipoprotein A-1 fused to interferon alpha in an interferon alpha-resistant murine tumor model.
    Vasquez M; Paredes-Cervantes V; Aranda F; Ardaiz N; Gomar C; Berraondo P
    Oncotarget; 2017 Jan; 8(3):5247-5255. PubMed ID: 28029653
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Initial expression of interferon alpha receptor 2 (IFNAR2) on CD34-positive cells and its down-regulation correlate with clinical response to interferon therapy in chronic myelogenous leukemia.
    Ito K; Tanaka H; Ito T; Sultana TA; Kyo T; Imanaka F; Ohmoto Y; Kimura A
    Eur J Haematol; 2004 Sep; 73(3):191-205. PubMed ID: 15287917
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preliminary study on the efficacy and safety of lamivudine and interferon alpha therapy in decreasing serum HBV DNA level in HBV positive transgenic mice during pregnancy.
    Li D; Xu DZ; Choi BC; Men K; Zhang JX; Lei XY; Yan YP
    J Med Virol; 2005 Jun; 76(2):203-7. PubMed ID: 15834875
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Anti-viral proteins: from interferon alpha to its receptor].
    Chieux V; Hober D; Chehadeh W; Wattr P
    Ann Biol Clin (Paris); 1999 May; 57(3):283-90. PubMed ID: 10377478
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Generation of a liver targeting fusion interferon and its bioactivity analysis in vitro.
    Cai G; Jiang M; Zhou Y; Gu X; Zhang B; Zou M; Zhou X; Bao J; Cao G; Zhang R
    Pharmazie; 2011 Oct; 66(10):761-5. PubMed ID: 22026157
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term follow-up after successful interferon therapy of acute hepatitis C.
    Wiegand J; Jäckel E; Cornberg M; Hinrichsen H; Dietrich M; Kroeger J; Fritsch WP; Kubitschke A; Aslan N; Tillmann HL; Manns MP; Wedemeyer H
    Hepatology; 2004 Jul; 40(1):98-107. PubMed ID: 15239091
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Scavenger receptor class B type I-mediated protection against atherosclerosis in LDL receptor-negative mice involves its expression in bone marrow-derived cells.
    Covey SD; Krieger M; Wang W; Penman M; Trigatti BL
    Arterioscler Thromb Vasc Biol; 2003 Sep; 23(9):1589-94. PubMed ID: 12829524
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatitis C virus replication is inhibited by 22beta-methoxyolean-12-ene-3beta, 24(4beta)-diol (ME3738) through enhancing interferon-beta.
    Hiasa Y; Kuzuhara H; Tokumoto Y; Konishi I; Yamashita N; Matsuura B; Michitaka K; Chung RT; Onji M
    Hepatology; 2008 Jul; 48(1):59-69. PubMed ID: 18459156
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interferon therapy in HCV-positive mixed cryoglobulinaemia: viral and host factors contributing to efficacy of the therapy.
    Mazzaro C; Carniello GS; Colle R; Doretto P; Mazzi G; Crovatto M; Santini GF; Tulissi P; Gregoretti M; Mazzoran L; Russo A; Silvestri F; Pozzato G
    Ital J Gastroenterol Hepatol; 1997 Aug; 29(4):343-50. PubMed ID: 9476189
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeted delivery of siRNA against hepatitis C virus by apolipoprotein A-I-bound cationic liposomes.
    Kim SI; Shin D; Lee H; Ahn BY; Yoon Y; Kim M
    J Hepatol; 2009 Mar; 50(3):479-88. PubMed ID: 19155084
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Viral covalently closed circular DNA in a non-transgenic mouse model for chronic hepatitis B virus replication.
    Takehara T; Suzuki T; Ohkawa K; Hosui A; Jinushi M; Miyagi T; Tatsumi T; Kanazawa Y; Hayashi N
    J Hepatol; 2006 Feb; 44(2):267-74. PubMed ID: 16226822
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic characteristics, pharmacodynamic effect and in vivo antiviral efficacy of liver-targeted interferon alpha.
    Rycroft D; Sosabowski J; Coulstock E; Davies M; Morrey J; Friel S; Kelly F; Hamatake R; Ovečka M; Prince R; Goodall L; Sepp A; Walker A
    PLoS One; 2015; 10(2):e0117847. PubMed ID: 25689509
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of Interleukin1β as an Amplifier of Interferon alpha-induced Antiviral Responses.
    Robichon K; Maiwald T; Schilling M; Schneider A; Willemsen J; Salopiata F; Teusel M; Kreutz C; Ehlting C; Huang J; Chakraborty S; Huang X; Damm G; Seehofer D; Lang PA; Bode JG; Binder M; Bartenschlager R; Timmer J; Klingmüller U
    PLoS Pathog; 2020 Oct; 16(10):e1008461. PubMed ID: 33002089
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Type I interferon rapidly restricts infectious hepatitis C virus particle genesis.
    Meredith LW; Farquhar MJ; Tarr AW; McKeating JA
    Hepatology; 2014 Dec; 60(6):1891-901. PubMed ID: 25066844
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Microstructured dextran hydrogels for burst-free sustained release of PEGylated protein drugs.
    Bae KH; Lee F; Xu K; Keng CT; Tan SY; Tan YJ; Chen Q; Kurisawa M
    Biomaterials; 2015 Sep; 63():146-57. PubMed ID: 26100344
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of IFNalpha bioavailability by MxA mRNA in HCV patients.
    Gilli F; Sala A; Bancone C; Salacone P; Gallo M; Gaia E; Bertolotto A
    J Immunol Methods; 2002 Apr; 262(1-2):187-90. PubMed ID: 11983232
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting Attenuated Interferon-α to Myeloma Cells with a CD38 Antibody Induces Potent Tumor Regression with Reduced Off-Target Activity.
    Pogue SL; Taura T; Bi M; Yun Y; Sho A; Mikesell G; Behrens C; Sokolovsky M; Hallak H; Rosenstock M; Sanchez E; Chen H; Berenson J; Doyle A; Nock S; Wilson DS
    PLoS One; 2016; 11(9):e0162472. PubMed ID: 27611189
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diverse Immunomodulatory Effects of Individual IFNα Subtypes on Virus-Specific CD8
    Dickow J; Francois S; Kaiserling RL; Malyshkina A; Drexler I; Westendorf AM; Lang KS; Santiago ML; Dittmer U; Sutter K
    Front Immunol; 2019; 10():2255. PubMed ID: 31608062
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preclinical studies on targeted delivery of multiple IFNα2b to HLA-DR in diverse hematologic cancers.
    Rossi EA; Rossi DL; Cardillo TM; Stein R; Goldenberg DM; Chang CH
    Blood; 2011 Aug; 118(7):1877-84. PubMed ID: 21680794
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.